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ABSTRACT (294) 
Objective: Multiple organ dysfunction syndrome (MODS) is characterised by simultaneous 
multiple organ failure, which is the leading cause of death in acute critically ill patients. 
However, what mediates MODS is not fully understood. The discovery of toxic effects by 
extracellular histones on different individual organs strongly suggests their involvement in 
MODS. In this study, we investigate whether circulating histones are major mediators of 
MODS in acute critical illnesses.  
Design: Combination of retrospective clinical studies and animal models with intervention. 
Setting: Intensive Care Unit (ICU) in a tertiary hospital and research laboratories 
Patients: 420 ICU patients, including sepsis (140), severe trauma (63), severe pancreatitis 
(89) and other admission diagnoses (128).  
Laboratory investigation: Cells from major organs treated with calf thymus histones or 
histone-containing sera. Animal models for sepsis, trauma and acute pancreatitis treated with 
anti-histone reagents.  
Intervention: Anti-histone reagents in in vitro, ex vivo and animal models. 
Measurement and Main Results:  Retrospective analysis of a prospectively recruited ICU 
cohort demonstrated a strong correlation between circulating histones and organ injury 
markers and Sequential Organ Failure Assessment (SOFA) scores. Ex vivo experiments 
showed that patient sera containing high histone levels were toxic to cultured cells from 
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different origins, suggesting their universal toxicity to multiple organs. Animal models of 
sepsis, trauma and pancreatitis further demonstrated a temporal correlation between histone 
levels and disease severity and multiple organ injury. Importantly, anti-histone reagents, i.e. 
anti-histone single-chain variable fragment (ahscFv) and non-anticoagulant heparin, could 
dramatically reduce multiple organ injury, particularly of the heart and lungs, and improve 
survival in mouse models.   
Conclusions: High levels of circulating histones are major mediators of MODS. Our results 
indicate that monitoring upon ICU admission could inform on disease severity and 
developing anti-histone therapy holds great potential of reducing MODS and improving 
survival of critically ill patients.   
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INTRODUCTION 
Multiple organ dysfunction syndrome (MODS) is characterised by dysfunction of two or 
more organs in acute critically ill patients who require intervention to maintain homeostasis 
in Intensive Care Units (ICU)(1, 2) . Affected patients have high mortality rates of around 30-
100%, depending on the number of dysfunctional organs. Therefore MODS has become the 
leading cause of morbidity and mortality in current ICU practice (3). Sepsis is the most 
common primary disease of MODS and causes more deaths than any single type of cancer (4). 
In the UK, sepsis alone causes 44,000 deaths and costs over 7.6 billion pounds annually.  The 
incidence of sepsis continues to increase by over 30% in the last 2 years (5). Recently, the 
third international consensus definitions for sepsis have altered previous focus on 
inflammation to life-threatening multiple organ dysfunction (6). This change reflects the 
importance of MODS in sepsis. 
MODS is mediated by harmful simultaneous effects to multiple organs rather than a chain 
reaction from one organ to another (7).  However, the identification of common mediators 
remains undefined. Coagulation activation, microcirculatory failure and oxygen deprivation as 
well as bacterial toxins have been proposed as potential mediators but have not been fully 
proven (8). In the last decade, the secondary hit theory by damage-associated molecular 
patterns (DAMPs) (9), particularly histones released from damaged cells, has attracted 
attention. Histones are well-conserved proteins essential in DNA packaging and gene 
regulation (10). During cell damage, nuclear chromatin is cleaved into nucleosomes, which 
are released extracellularly (11) and further degraded into individual histones (12). 
Nucleosomes/histones are rapidly cleared by the liver (13) and are rarely detected in blood, 
unless extensive tissue damage or cell death occurs in a short time period, e.g in acute critical 
illnesses.  
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Histones are highly cationic proteins that are able to interact with negatively charged 
phosphate groups of double-stranded DNA and phospholipid bilayers to condense chromatin 
and disrupt cell membranes, respectively (14, 15). Histone disruption of cell membranes cause 
abnormal ion flow, leading to loss of membrane potential with calcium overload and 
consequent cell damage (15). Histones are also the natural ligands of TLR-2, -4 and -9 
receptors (16, 17) and serve as the most important DAMPs in activating immune cells, 
inflammasomes, and release of pro-inflammatory cytokines (18, 19), and enhancing thrombin 
generation through platelet activation and aggregation (20, 21). Low levels of histones 
activate endothelium to release von Willebrand factor (VWF) (22), recruit leucocytes/platelets 
and reduce thrombomodulin-dependent protein C anticoagulant effects (23, 24), whilst  high 
histone levels directly cause endothelial damage (15, 25) and are strongly associated with the 
development of disseminated intravascular coagulation (DIC) (26).  
Although extracellular histones have been reported to damage single organs (15-17, 25, 27-31) 
and anti-histone reagents, such as neutralizing antibodies (15, 25), heparins (29, 32, 33) and 
C1 esterase inhibitors (34) are able to reduce histone toxicity, it is not fully clear whether 
circulating histones are the major secondary hit by mediating MODS development. In this 
study, we aligned clinical studies with animal models for severe trauma, acute pancreatitis 
and sepsis, to clarify the roles of circulating histones in MODS development in these common 
acute critical illnesses.   
METHODS 
Study design and patients 
We retrospectively assessed a prospectively recruited cohort of adult patients admitted to the 
general ICU at the Royal Liverpool University Hospital (RLUH) between Jan 2008 and Jan 
2014. Patients with preconditions that may cause biases were excluded (Supplemental Figure 
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1). Clinical data and blood samples were collected on admission and then daily up to day 4 in 
accordance to protocol (Ref: 07/H1009/64) approved by Northwest Research and RLUH 
Ethics Committees and protocol (Ref: 13/NW/0089) approved by NRES Committee North 
West-Haydock. MODS was defined as SOFA scores ≥5. Blood samples were also collected 
from healthy donors according to protocol (RETH000685) approved by Committee on 
Research Ethics, University of Liverpool. All normal control and patient plasma samples 
were snap frozen and stored at -80oC until analysis. Samples used for assays in this study had 
not previously been thawed and re-frozen.  
Mice  
C57/BL6 male, 8-10 week old mice from Beijing Vital River Laboratory Animal Technology 
were housed and used in sterile conditions at the Research Centre of Genetically Modified 
Mice, Southeast University, China. All procedures were performed according to State laws 
and monitored by local inspectors in compliance with British Home Office laws. CZX holds 
the full animal license for use of mice.  
Disease-specific models 
The mouse trauma model by fall of a heavy object (15), sepsis model by Cecal Ligation and 
Puncture (CLP) (35), and acute pancreatitis models using cerulein and sodium taurochlorate 
(TCL) (36, 37) was generated with different severities. The detailed procedures are described 
in Supplemental Data.  
Statistical analysis 
Human data are presented as median and interquartile ranges [1st, 3rd quartiles]. Differences 
in medians of continuous clinical variables between two (Mann Whitney U test) or more 
groups (Kruskall-Wallis test) were tested. Continuous variables used in ex vivo and in vivo 
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experiments were normally distributed and are presented as mean ± standard deviation (SD). 
Differences in means between more than two groups were compared using ANOVA test 
followed by Student-Newman-Keuls test. Correlation between circulating histone and organ 
injury markers utilized Spearman’s rank test for human data and linear regression for mouse 
data based on the distribution of the data. To test whether circulating histones were predictors 
of MODS development (48-72h post ICU admission) and 28-day mortality, logistic 
regression and Receiver Operating Characteristic (ROC) analysis were performed. Survival 
time comparison was performed using Log rank test. P value (two-tailed) <0.05 was 
considered statistically significant. 
RESULTS 
Elevated circulating histone levels in human critical illnesses are associated with MODS 
To determine the clinical relevance of circulating histones, we examined a cohort of 
prospectively recruited 420 ICU patients and their clinical characteristics are described in 
Supplemental Table 1. Collectively, the data demonstrated that circulating histone levels 
(median 24.7µg/ml [quartiles 8.0µg/ml, 46.7µg/ml]) are significantly elevated compared to 
normal healthy donors (1.3 µg/ml [0, 2.1]) (Figure 1A) (P<0.001). Among the subgroups of 
critical illnesses, circulating histone levels on admission were significantly higher in patients 
with either an admission diagnosis of sepsis (n=140) (34.0µg/ml [13.2, 60.5]), severe trauma 
(n=63) (23.8 µg/ml [11.1, 45.2] and severe pancreatitis (n=89) (28.7µg/ml [11.6, 63.8]), 
compared to others (n=128) (9.2 µg/ml [1.3, 30.0]) (P<0.05). There were no statistical 
differences in terms of circulating histone levels between sepsis, trauma and pancreatitis 
patients (Figure 1B). Using Spearman’s rank correlation, we found strong correlations 
between circulating histone levels and clinical organ injury biomarkers, including blood urea 
nitrogen (BUN for renal function, r=0.496, P<0.0001), alanine aminotransferase (ALT for 
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liver injury, r=0.545, P<0.0001), cardiac troponin T (cTnT for cardiac injury, r=0.607, P<0.01) 
and PaO2/FiO2 (P/F ratio for lung function, r=0.360. P=0.015).   
Strong correlation between circulating histones and Sequential Organ Failure Assessment 
(SOFA) scores was also observed (r=0.574, P<0.0001). The levels of circulating histones in 
patients with MODS (SOFA score ≥5) were significantly higher than those without (median 
30.1µg/ml [quartiles 7.3, 63.2] vs 10.8µg/ml [4.3, 30.1], P<0.0001) (Figure 1C). Similarly, 
circulating histones were higher in patients who died within 28 days of ICU admission than 
patients who survived (32.7µg/ml [14.4, 66.9] vs 20.1µg/ml [6.7, 40.5], P< 0.0001) (Figure 
1D). These data suggest that levels of circulating histones reflect severity of disease and their 
presence may contribute to MODS and mortality, particularly at high levels. ROC analysis 
demonstrated that admission histone levels could predict MODS development 48-72h after 
ICU admission (AUC 0.617, P=0.001), which is supported by a logistic regression model 
(odds ratio = 1.012 [1.003, 1.020] (P=0.005)). Similarly, ICU admission histone level could 
predict 28 day mortality (AUC 0.625 (P<0.001), odds ratio = 1.006 (1.002, 1.010) 
(P<0.001)).Sera from patients with high histone levels are cytotoxic and not cell-type 
specific  
Histone-spiked normal sera from healthy donors were found toxic to cultured human 
endothelial (EAhy926) cells in a dose-dependent manner. At or above 30µg/ml histones, cell 
viability was significantly reduced, which could be reversed by addition of either 50µg/ml 
heparin or ahscFv (Figure 2A). When endothelial cells were incubated with ICU patient sera 
containing circulating histones >30µg/ml, their viability was significantly reduced (Figure 
4B). Conversely, cell viability was not significantly reduced when they were incubated with 
sera with undetectable histones or <30μg/ml. Importantly, addition of ahscFv or non-
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anticoagulant heparin could significantly reduce the cytotoxicity by over 90% (Figure 2B), 
demonstrating that the major toxic factors in these patients’ sera were elevated histones.  
To demonstrate that circulating histones are also toxic to primary cells from different organs, 
primary kidney epithelial cells, immortalized liver cells, primary lung epithelial cells, and 
cardiomyocytes were incubated with 50μg/ml calf thymus histones or pooled patients’ sera 
containing about 50μg/ml circulating histones. Figure 2C shows that cell viability was 
reduced to comparable levels in all cell types. This data indicates that histones are non-
selectively toxic to all tested cells and high histone levels may damage most organs 
simultaneously.  
Circulating histone levels increase with increasing disease severity in mouse models 
To comprehensively investigate the role of elevated circulating histones in vivo, we used 
different mouse models for the major acute critical illnesses and found circulating histone 
levels increased significantly with increasing severity of trauma, sepsis and pancreatitis 
(Figure 3A-C). In the trauma model, circulating histones increased significantly 1h after 
trauma to peak at 8h (Supplemental Figure 2A). At 8h, circulating histones were 
22.7±8.3µg/ml (Mean±SD) in mild, 80.3±14.2µg/ml in moderate and 242.3±132.9µg/ml in 
the severe model (Figure 3A, P<0.01). In the sepsis models, elevated histone levels were 
significantly elevated 2h after CLP induction and peaked at 16h (Supplemental Figure 2B). At 
this time, circulating histone levels were 74.3±15.9µg/ml in less severe and 129.3±43.7µg/ml 
in severe sepsis (Figure 3B). In the pancreatitis models, cerulein (4x) and cerulein (12x)-
induced pancreatitis, circulating histones showed a significant increase at around 6h after the 
first dose of cerulein and peaked at approximately 14-20h. In TCL-induced severe pancreatitis, 
circulating histones began to increase 2h following induction and peaked at approximately 
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16h (Supplemental Figure 2C). At 16h, circulating histones were 3.7±3.5µg/ml in cerulein 
(4x), 90.2±35.9µg/ml in cerulein (12x) and 155.0±79.1µg/ml in the TCL model (Figure 3C).  
Circulating histone levels strongly correlate with organ injury markers in mouse models 
Circulating biomarkers for liver, renal and cardiac injury as well as lung injury scores based 
on H&E stained sections were significantly elevated in these mouse models compared to 
mock controls (Supplemental Table 2). Typical H&E stained lung sections are presented in 
Supplemental Figure 3, showing increased thickness of alveolar walls, extensive neutrophil 
infiltration and hyaline membrane formation. In contrast, mock procedures did not cause 
obvious changes in lung morphology. No obvious morphological changes were identified in 
heart, liver and kidney sections (Data not shown).  No substantial numbers of apoptotic cells 
were observed by immuno-histochemical staining (using anti-active caspase-3 from Abcam) 
of the lungs, liver, heart and kidneys but substantial numbers were found in the spleen and 
thymus (Supplemental Figure 4).  Linear regression analysis demonstrated that elevations in 
circulating biomarkers for liver (ALT, r=0.588, P<0.001) (Figure 4A), for renal (BUN, 
r=0.539, P<0.001) (Figure 4B), for cardiac (cTnI, r=0.605, P<0.001) (Figure 4C) and lung 
injury scores (r=0.726, P<0.001) (Figure 4D), strongly correlated with circulating histone 
levels in these mouse models.  
Anti-histone reagents significantly reduce multiple organ injury and mortality in mouse 
models 
To examine for a causal relationship between elevated circulating histones and MODS, 
ahscFv and non-anticoagulant heparin were used (Figure 5A-C, Supplemental Table 2). We 
found that anti-histone reagents significantly reduced organ injury in severe trauma (5A), 
severe sepsis (5B) and TCL pancreatitis (5C) models.   The cTnI was most affected by anti-
histone treatment and its levels were reduced by about 90% compared to untreated models, 
11 
 
whereas BUN and ALT were only reduced by 30-60%. Morphologically, lung injury as 
indicated by increased alveolar wall thickness, extensive neutrophil infiltration in interstitial 
tissues and alveoli, and hyaline membrane formation, was also significantly improved by anti-
histone treatments (Supplemental Figure 5). Accordingly, lung injury scores were 
significantly reduced (Figure 5D).  In terms of mortality, anti-histone reagents significantly 
increased the survival time and reduced mortality in 72h after CLP in the severe sepsis model. 
Administration of anti-histone reagents before CLP (Figure 5E) appeared more effective than 
at 6h after CLP (Figure 5F) but there was no statistical difference. This data demonstrates that 
elevations in circulating histones are major mediators of MODS and also contribute to 
mortality.   
DISCUSSION 
Multiple but not single organ dysfunction is the most common pathological feature of critical 
illnesses and appears to be the major contributor of lethality. However, mediators of 
simultaneous dysfunction of multiple organs are unclear and not fully clarified. In this study, 
we have investigated the roles of circulating histones in 3 of the most common human critical 
illnesses in alignment with corresponding animal models where anti-histone treatment could 
be used. Extracellular histones are not detectable in healthy donors but high histone levels 
were found in all the 3 common acute critical illnesses, i.e. sepsis, trauma and pancreatitis in 
both human and animal models. Nearly all critically ill patients showed elevated circulating 
histones compared to healthy donors. In nearly two-thirds of our ICU population, histone 
levels were above 30µg/ml, a previously determined threshold for cytotoxicity (26). 
Furthermore, circulating histone levels were significantly associated with disease severity and 
MODS as well as to adverse clinical outcomes. The fact that anti-histone reagents could 
detoxify circulating histones to significantly alleviate MODS and improve survival rates 
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strongly indicates that high circulating histone levels are not only biomarkers of disease 
severity but act as a secondary hit to directly contribute to MODS and poor outcomes.  
The source of circulating histones is still not clearly defined in the different critical illnesses. 
It is most likely that in trauma, circulating histones are released from extensively damaged 
tissues. The early elevation of circulating histones (within 1h) and its significant correlation 
with the extent of injury strongly supports this argument. In severe pancreatitis, the source of 
histones is not so obvious. Necrosis of the pancreas is very likely a major source of circulating 
histones. However, histone levels increase within 24h of onset but no obvious pancreatic 
necrosis can usually be detected in patients at this time point (38). There may be therefore 
other sources of histones. We had previously observed that extensive neutrophil loss occurs 
prior to pancreatic necrosis and correlates with circulating histone levels, within 24h of 
admission of patients with acute pancreatitis (39). This data could suggest that neutrophil 
death or NETosis could be another major source of circulating histones, particularly in the 
early stage of severe pancreatitis. In sepsis, the source of circulating histones also remains 
unclear. Organ injury may be the source of circulating histones but limited cell death was 
observed in major organs (Supplemental Figure 4), which therefore suggests that this is not 
the major source. NETosis or immune cell death, particularly in spleen and thymus was 
extensive (Supplemental Figure 4) and this might be the major contributor (40-42) but further 
investigation is required. Since histones themselves can cause cell injury by forming pores on 
cell membrane, similar to pyroptosis, it is likely that a vicious cycle may exist to damage 
more cells and release more histones.  
The mechanisms of histone-mediated MODS may be divided into direct and indirect effects. 
In behaving like endogenous pore-forming toxins, circulating histones are non-selectively 
toxic to cells from different organs (Figure 2) and thereby injure multiple organs 
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simultaneously (27, 28, 43). Indirect effects may be due to activation of immune responses or 
coagulation activation (44, 45). An extensive pro-inflammatory state with microcirculatory 
impairment may especially compromise multiple organs (19). Conversely, histone release also 
triggers protective mechanisms to recalibrate homeostasis, such as increase in acute phase 
protein,  C-reactive protein, to neutralise histone toxicity, and interaction with complement 
component 4 to inhibit complement activation (46, 47).  
Identification of severely ill patients is important in clinical practice, particularly those that 
require intensive care support. Irrespective of the source of circulating histones, high levels 
could represent severe inflammation, infection or tissue damage (15, 25, 36, 48), highlighting 
their clinical usefulness as a biomarker of disease severity. Previously, we demonstrated that 
high histone levels in a non-ICU setting could identify patients with pancreatitis at risk of 
developing persistent organ failure (39). This current ICU-based study demonstrates that this 
approach could be extended to the majority of critical illnesses. While this study is limited to 
a single ICU, our demographics and performance are consistent with comparable units 
according to the Intensive Care National Audit and Research Centre (ICNARC) data. 
Measuring circulating histones could identify those deteriorating patients that need critical 
attention.  
Anti-histone therapy has been proposed for many years (25) but no specific therapy has 
become clinically available. One option would be the development of anti-histone antibodies, 
but there are limitations in terms of production, purification and the risk of host auto-
antibodies.  Non-anticoagulant heparin has been demonstrated to be a viable and effective 
alternative anti-histone reagent in histone infusion models (33, 49). Our data in patient ex-
vivo experimentation complemented by relevant in vivo modelling advances the translational 
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potential of neutralising circulating histones using non-anticoagulant heparin to reduce 
MODS and mortality in critically ill patients. 
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Figure legends 
Figure 1. Circulating histones are elevated in sepsis, pancreatitis and trauma patients. 
(A) Circulating histones were quantified in the plasma of normal healthy donors (n=10) and 
ICU patients (n=420). Mann-Whitney U test shows significant increases in circulating 
histones in ICU patients compared to healthy controls, P<0.0001. (B) Patients were stratified 
based on an admission diagnosis and circulating histone levels were examined. Kruskall-
Wallis test shows significantly elevated circulating histones in sepsis (n=140), pancreatitis 
(n=89) and trauma (n=63) patients compared to those with other admission diagnoses (n=128), 
P<0.01. Circulating histones levels were analyzed in ICU patients who developed MODS and 
those who did not (C) along with those who survived and died (D). Mann–Whitney U test 
shows significant difference. 
Figure 2. Sera from patients with high levels of histones are cytotoxic. (A) Sera from 
healthy donors spiked with calf thymus histones (A) or sera isolated from patients with high 
levels of circulating histones (B) were used to treat cultured EAhy926 endothelial cells in the 
absence or presence of anti-histone reagents, heparin or ahscFv (50 µg/ml) for 1h and then 
viable cells were detected.  (C) Cells derived from different organs, including cardiomyocytes 
(Heart), lung epithelial cells (Lung), liver cells (Liver) and kidney cells (Kidney), were treated 
with calf thymus histones (50 µg/ml) or pooled patients’ sera with approximately 50 µg/ml 
endogenous histones. Sera with undetectable histones were used as controls and their resultant 
cell viability was set as 100%. Means±SD of cell survival rates from at least 3 independent 
experiments are presented. ANOVA test, *P<0.05 when compared to sera without histones. 
#P<0.05 when compared to histone in sera alone at the indicated concentrations.  
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Figure 3. Circulating histones are elevated in mouse models along with increasing 
severity. Comparison of the peak circulating histone levels in normal mice (N=3), mild 
(N=12), moderate (N=12) and severe (N=15) trauma (A), mock CLP (N=3), less severe 
(N=12) and severe (N=15) sepsis (B) and saline control (N=3), mock TCL (n=3), cerulein (4x, 
N=10), cerulein (12x, N=11) and TCL (N=11) pancreatitis (C) mouse models are presented as 
Means±SD. ANOVA test *P<0.05 when compared to 0h. #P<0.05 when compared to the less 
severe model.  
Figure 4. Circulating histones strongly correlate with organ injury markers in mouse 
models.  The correlation of circulating histones in all 3 mouse disease models (excluding all 
controls) with parameters of organ injury, ALT for liver (r=0.588, N=92, P<0.001) (A), BUN 
for renal (r=0.539, N=92, P<0.001) (B), cTnI for cardiac (r=0.605, N=92, P<0.001) (C) and 
lung injury scores (r=0.726, N=46 (randomly selected from each group), P<0.001) (D) were 
analyzed using linear regression. 
Figure 5. Anti-histone reagents reduce organ injury and mortality in mouse models. 
Anti-histone reagents, i.e. non-anticoagulant heparin (Sigma, 25 mg/kg) and ahscFv (20 
mg/kg) were used to treat mice with severe trauma (A), severe sepsis (B) and taurochlorate 
(TCL)-induced pancreatitis (C). Changes of organ injury markers are presented as percentage 
by setting that without anti-histone treatment as 100%. Means±SD are presented. ANOVA 
test, * P<0.05 when compared to untreated. (D) Changes in lung injury scores before and after 
treatments are shown. ANOVA test, *P<0.05 when compared with mock group, #P<0.05 
when compared with model alone group. (E-F) Survival curves of severe sepsis model 
untreated or treated with anti-histone reagents starting before CLP (E) or 6h after CLP (F) 
over a 72h period. Log rank test, P<0.01 when compared to CLP alone. 
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